Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
26 Japan Drug Makers Log 4% Fall in Workforce as Downtrend Continues Unabated: FY2019 Securities Reports
Twenty-six Japanese pharmaceutical makers saw their total workforce decline by 4.0% in FY2019 over the previous year, according to their annual securities filings tallied by Jiho. The latest number reflects a series of job cuts implemented towards the end of…
To read the full story
Related Article
- Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
- 26 Japan Drug Makers’ Annual Pay Averages 8.21 Million Yen, 5 Firms Top 10 Million Yen Mark
July 7, 2021
- Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
BUSINESS
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Amitiza Most Heavily Pitched Medicine for Hospital Doctors in November: Intage
January 10, 2025
- FDA Accepts Re-Submission of Izervay to Buttress Label
January 10, 2025
- Keytruda Grabs Best-Seller Crown for 15th Month in December: Encise
January 10, 2025
- Padcev Broadens Label for Keytruda Combo in China: Astellas
January 9, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…